Enlarge / A father cares for his eight-and-a-half-month-old son, who is in the intensive care unit of the pediatric clinic at St. Joseph Hospital in Berlin with a respiratory infection and is receiving non-invasive ventilation (CPAP ventilation).Getty | Christoph Soeder
A committee of independent expert advisors for the Food and Drug Administration on Thursday voted largely in favor of the agency approving Pfizer’s vaccine for protecting infants from the common respiratory virus RSV—respiratory syncytial (sin-SISH-uhl) virus—which can be deadly to infants.
The vaccine, provisionally dubbed Abrysvo, is given to pregnant people between 24 and 36 weeks of pregnancy, allowing protective
→ Continue reading at Ars Technica